Swiss drug maker Novartis AG says its Exelon skin patch for treatment of mild to moderate Alzheimer's disease has been approved by the US Food and Drug Administration, AFX News reported Monday. The drug itself received FDA approval last year.
The once-daily patch offers continuous drug delivery for 24 hours and provides a novel approach to Alzheimer's treatment, according to Novartis.
The company said the efficacy of the Exelon patch is similar to that of the highest doses of Exelon capsules and provides significant improvements in patients' memory and ability to perform everyday activities, compared to a placebo.
Novartis also said the patch minimises gastrointestinal side effects caused by the oral form of the drug, AFX News reported. – (HealthDayNews)
Alzheimer's and Dementia Centre